Tofacitinib in the treatment of cardiac sarcoidosis: towards steroid-sparing disease management

Key Points

• This research aims to evaluate the effectiveness of tofacitinib in managing cardiac sarcoidosis, particularly in reducing the need for corticosteroids.
• Evaluated eight patients with treatment-refractory cardiac sarcoidosis
• Monitored changes in myocardial inflammation
• Assessed corticosteroid dependency levels
• Seven out of eight patients showed significant reduction in myocardial inflammation
• Most patients reduced their corticosteroid dependency
• Indicates potential for tofacitinib in complex patient management

Abstract